55 search results for: Bullous Pemphigoid
What We Know About Bullous Pemphigoid (BP): Challenges of the Various Clinical Manifestations, Diagnosis, and Burden for Patients and Caregivers
In this ADVENT symposium at the 2024 EADV meeting, Professor Joost Meijer highlights the heterogeneous nature of BP and the resultant burden for patients.
Time to Act: Reducing the Impact of Uncontrolled Disease Through Early Intervention
Dr Jason Hawkes describes the importance of early intervention for patients with uncontrolled skin diseases and the effectiveness of evidence-based management strategies, sharing a patient case and his clinical insights with chronic spontaneous urticaria. Drs Eichenfield, Elmariah, and Culton join to review the burdens faced by patients with atopic dermatitis, prurigo nodularis, and bullous pemphigoid, respectively.
Bullous Pemphigoid: Exploring New Frontiers
Highlights from the ADVENT educational symposium at EADV 2024 discussing the current understanding of the science and treatment landscape in bullous pemphigoid (BP).
The Patient's Path: Unraveling the Diagnosis and Burden of Bullous Pemphigoid
Follow Janet, a hypothetical patient, as she navigates the difficult journey of bullous pemphigoid, starting with symptom onset to diagnosis.
Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation
This 2-hour educational program delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, prurigo nodularis, bullous pemphigoid, and chronic spontaneous urticaria. It will highlight both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies. Experts will guide the audience through diverse patient cases to illuminate diagnostic nuances and the pathophysiology of each condition. These cases will also highlight the importance of shared decision-making and the broadening of treatment goals beyond symptom control. Dynamic panel discussion and active audience participation will be facilitated through real-time polling and curated Q&A sessions.
Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation
This symposium delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid. It highlights both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies through a series of engaging panel discussions with Drs Eichenfield, Elmariah, Culton, and Hawkes.
Shared and Distinct: The Role of Type 2 Inflammation in Skin Diseases
Dr Donna Culton walks through the pathophysiology of type 2 inflammation in inflammatory skin diseases, using bullous pemphigoid as an example. Drs Eichenfield, Elmariah, and Hawkes join to discuss the role of type 2 inflammation across atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, respectively.
Heterogeneous Presentation and Diagnosis in Bullous Pemphigoid
Dr. Donna Culton describes the heterogeneous presentation and diagnosis of bullous pemphigoid at EADV 2025
Beyond Age: Unraveling the Mortality Risk in Bullous Pemphigoid
Dr. Donna Culton discusses the elevated mortality risk in patients with bullous pemphigoid at EADV 2025
Under the Skin: Autoimmunity and Type 2 Inflammation in Bullous Pemphigoid (BP)
Join Drs. Victoria Werth and Teri Greiling as they explain the autoimmunity driving bullous pemphigoid (BP), as well as the important role type 2 inflammation plays in BP.
Heterogeneous Clinical Presentations and Diagnostic Challenges With Bullous Pemphigoid (BP)
Join Dr. Teri Greiling as she discusses the heterogeneous clinical presentations seen in bullous pemphigoid (BP). She also shares diagnostic challenges, including the unclear epidemiology and the extensive differential diagnoses faced by patients with BP.
